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Performing drug screening, of physiologically relevant three-dimensional (3D) tumor models, for 
personalized treatment remains challenging, due to the small amount of tissue available from most 
biopsies. New microfluidic technologies, enabling greater control over cell positioning and fluid 
behavior at the micro-scale, allow extensive testing of anticancer agents on human tumor tissue 
preparations in 3D and offer new solutions for the development of anticancer compounds and 
personalized medicine. We have developed a microfluidic platform for extensive drug screening of 
tumor biopsies in a cost-effective manner and validated the system with tumor prostate patient samples. 
As a typical drug screening assay, up to 22 drug concentration-response curves could be generated from 
a single biopsy, within a time frame of up to 4 weeks. Biopsy tissue, grown as a heterogeneous co-
culture from the primary sample, was prepared as cancer-cell enriched multicellular spheroids, cultured 
for 3 to 5 days prior to the application of a panel of standard-of-care drugs for prostate cancer. Readouts 
were obtained via bright-field and epifluorescence microscopy. The microfluidic platform was designed 
to be operated entirely without the need of external fluid actuation, with the microfluidic network 
capable of generating long-lasting, stable and repeatable drug concentration gradients across arrays of 
240 spheroids. Outcomes were generated as 8-point drug concentration response curves per device, with 
each drug concentration tested on at least 24 spheroids. In-house developed software was used to 
analyze bright-field and fluorescent images to provide readouts of spheroid growth and viability, as 
well as information on drug penetration and drug efficacy over time. Following platform and assay 
validation using cancer cell lines, proof-of-concept screening was performed on prostate biopsies from 
2 different patients. Results showed that biopsy-derived spheroids were more resistant to treatment than 
LNCaP spheroids, a prostate cancer cell line. For one biopsy, spheroids were sensitive to docetaxel, but 
resistant to enzalutamide, despite the presence of intact androgen receptors. This preliminary data 
outlines how this technology could become a useful tool to investigate patient-specific drug resistance 
and to test novel anticancer agents in a cost-effective manner, based on maximized screening of human 
tumor tissue in a 3D format. 
